Therapy for brain tumors is complicated by the blood-brain barrier (BBB), which impedes delivery of chemotherapeutic agents to the central nervous system (CNS). Osmotic BBB disruption (BBBD) is a method to deliver agents across the BBB to infiltrating tumor cells. The Brain Tumor Program Review Group (PRG) recently identified the areas of drug delivery,targeted chemotherapy, imaging, and the BBB as priorities forresearch in CNS metastases. During the previous funding period, we addressed the PRG points by showing that route of delivery of a tumor-specific immunoconjugate(BR96-DOX) is directly related to survival in an implanted metastasis model, and combination protocols with radiotherapy further improved survival. The current question is how to further extend this paradigm in the laboratory and the clinic by focusing on the BBB, ~to examine issues in delivery of antitumor agents to brain tumors and to evaluate the efficacy of therapeutic approaches.
In Aim 1, we plan to expand our current implanted CNS metastatic tumor model in nude rats to a hematogenous CNS metastatic model. We propose to assess tumor growth by using a novel magnetic resonance (MR) imaging approach using super- paramagnetic iron particles to detect CNS tumors prior to conventionalimaging.
Aim 2 will investigatetherapeutic approaches for CNS metastases. We will determine if protein bindingimpactsCNS chemotherapeutic delivery and efficacy. Additionally, we will assess targeted delivery of the BR96-DOX immunoconjugate used in conjunction with standard chemotherapy and external beam radiotherapy.
In Aim 3 we will test the hypothesis that the thiol N- acetylcysteine (NAC) with or without sodium thiosulfate (STS), may ameliorate the bone marrow toxicity of combination chemotherapy/radiation protocols without compromising CNS chemotherapyefficacy. Finally,in Aim 4 a clinical phase 1trial of NAC is proposed. We hypothesize that NAC administered i.a. caudallyin the aorta will be safe in patients and prevent myelosuppresion in combination with high dose chemotherapy given into the vertebral and carotid arteries cephalad. Our overall hypothesis is that CNS enhanced delivery and combination therapies in models of CNS metastasis will increase anti-tumor efficacy as assessed by serial MR imaging, tumor volumetrics, and survival, whileminimizingtoxicity withchemoprotection. Laboratory studies of BBBD-enhanced chemotherapy have been translated intoclinical trials, and excitingefficacy has been demonstrated in primary CNS lymphoma. This revised competitive renewal is the continuation of the original 1978 surgical CREG, and is responsive to the priorities established in July 2000 by the joint NINDS and NCI Brain Tumor PRG.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37NS044687-25
Application #
7230931
Study Section
Special Emphasis Panel (ZRG1-BDCN-2 (07))
Program Officer
Jacobs, Tom P
Project Start
1988-02-01
Project End
2009-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
25
Fiscal Year
2007
Total Cost
$600,718
Indirect Cost
Name
Oregon Health and Science University
Department
Neurology
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Ambady, Prakash; Szidonya, Laszlo; Firkins, Jenny et al. (2018) Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. Leuk Lymphoma :1-4
Netto, Joao Prola; Schwartz, Daniel; Varallyay, Csanad et al. (2016) Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab. Fluids Barriers CNS 13:23
McConnell, Heather L; Schwartz, Daniel L; Richardson, Brian E et al. (2016) Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. Nanomedicine 12:1535-42
Muldoon, Leslie L; Pagel, Michael A; Netto, Joao Prola et al. (2016) Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. J Neurooncol 126:447-54
Muldoon, Leslie L; Wu, Y Jeffrey; Pagel, Michael A et al. (2015) N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. J Neurooncol 121:433-40
Lal, Sangeet; Kersch, Cymon; Beeson, Kathleen A et al. (2015) Interactions between ?v-Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain. PLoS One 10:e0131842
Pishko, Gregory L; Muldoon, Leslie L; Pagel, Michael A et al. (2015) Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids Barriers CNS 12:5
Doolittle, Nancy D; Muldoon, Leslie L; Culp, Aliana Y et al. (2014) Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. Adv Pharmacol 71:203-43
Gahramanov, Seymur; Varallyay, Csanad; Tyson, Rose Marie et al. (2014) Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncol 3:389-400
Farrell, Brian T; Hamilton, Bronwyn E; Dósa, Edit et al. (2013) Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. Neurology 81:256-63

Showing the most recent 10 out of 49 publications